CN105943186A - Establishment method for chronic high intraocular pressure animal model - Google Patents
Establishment method for chronic high intraocular pressure animal model Download PDFInfo
- Publication number
- CN105943186A CN105943186A CN201610249471.5A CN201610249471A CN105943186A CN 105943186 A CN105943186 A CN 105943186A CN 201610249471 A CN201610249471 A CN 201610249471A CN 105943186 A CN105943186 A CN 105943186A
- Authority
- CN
- China
- Prior art keywords
- intraocular pressure
- animal model
- schlemm
- chronic
- building
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 27
- 230000004410 intraocular pressure Effects 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 25
- 238000010171 animal model Methods 0.000 title claims abstract description 18
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 239000000835 fiber Substances 0.000 claims abstract description 16
- 230000000903 blocking effect Effects 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 6
- 238000011616 hypertension animal model Methods 0.000 claims description 14
- 210000002159 anterior chamber Anatomy 0.000 claims description 11
- 210000000795 conjunctiva Anatomy 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- -1 polypropylene Polymers 0.000 claims description 6
- 206010002091 Anaesthesia Diseases 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 230000037005 anaesthesia Effects 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 210000003786 sclera Anatomy 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000004087 cornea Anatomy 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 abstract description 25
- 230000007246 mechanism Effects 0.000 abstract description 11
- 210000001328 optic nerve Anatomy 0.000 abstract description 9
- 210000001742 aqueous humor Anatomy 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 208000030768 Optic nerve injury Diseases 0.000 abstract description 3
- 230000037361 pathway Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 206010020852 Hypertonia Diseases 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 206010030043 Ocular hypertension Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010023683 lagophthalmos Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940089982 healon Drugs 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D1/00—Surgical instruments for veterinary use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided is an establishment method for a chronic high intraocular pressure animal model. Through placing materials to block an outflow pathway of aqueous humor by operation, a glaucoma animal model which is increased in intraocular pressure and damaged in optic nerve is made. Increased intraocular pressure is maintained stable, and the intraocular pressure is easy to obtain and operate. The obtained model is advantaged in stable intraocular pressure increasing, low fluctuation, long high intraocular pressure duration time, and controllable target intraocular pressure. The intraocular pressure of the chronic high intraocular pressure animal model made by the method can be regulated according to different Schlemm blocking ranges. According to Schlemm pipe diameters of different animal kinds, fiber conduits in different specifications and dimensions can be selected, so as to complete blocking of the Schlemm pipe, and generate chronic high intraocular pressure models of various kinds of animals. Preferably establishing modeling animals and modeling methods fit with clinic in chronic high intraocular pressure glaucoma mechanism research provides foundation for chronic glaucoma optic nerve injury mechanism.
Description
Technical field
The present invention relates to medical animal model field, be specifically related to the method for building up of a kind of chronic intraocular hypertension animal model.
Background technology
Glaucoma is a kind of irreversibility optic nerve degeneration, for whole world second diseases causing blindness.The pathogenesis of its complexity is the most still not very clear, although Bulbi hypertonia is not the single factor that glaucoma regards infringement, but Bulbi hypertonia is one of factor the most dangerous in Deterioration of Optic Nerve in Glaucoma generation and development mechanism.In GLAUCOMA RESEARCH field, animal model has become important research tool.Glaucoma animal model has important effect for the damage mechanisms and remedy measures being better understood from glaucomatous optic neuropathy.Bulbi hypertonia is the topmost risk factor of Deterioration of Optic Nerve in Glaucoma, so the animal model of most of GLAUCOMA RESEARCH remains induced animal Bulbi hypertonia, and then studies the aspects such as the physiology of glaucoma, pathology, pharmacology.Preferably experimental animal model requires: its construction method is simple, with low cost, it is easy to raise and control, and the intraocular pressure of rising remains stable, and the distinctive pathological change of retina optic nerve occurs.
The animal being currently used for making glaucoma model is low mammal such as grade, mainly has rabbit, Mus, monkey.Although Mus is prone to transgenic technology transformation and breeding, and the structure of rathole is similar with human eye at a lot of aspects, and such as girder, Schlemm pipe, corpus ciliare, retinal vessel etc., but rathole is relatively small, is unfavorable for being operated.The Ocular hypertensive model of the monkey of induced with laser is the optimal Bulbi hypertonia animal model generally acknowledged at present, but because involving great expense, operates more complicated, and domestic application is few.Although lagophthalmos has Morphological Differences with the chamber-angle structure of human eye, but ah outflow passage is identical, has continuous print endotheliocyte liner.And rabbit price is inexpensive, personality is docile, be easily obtained and operate, therefore rabbit is most commonly used for making the laboratory animal of glaucoma model.
It is divided into according to Bulbi hypertonia Forming Mechanism and medicine site of action and acts on angle of anterior chamber (and girder) type, such as injected into anterior chambers hyaluronic acid, methylcellulose, hemocyte, Carbomer liquid, back room injection 5. Chymotrypsin, laser photocoagulation trabecular reticulum, the method such as eyes external corticosteroid hormone；Act on the most conventional scleral surface intravenous injection hypertonic saline method (Morre-Morrison model) of sclera aqueous humor drains intravenous type, burn episcleral aqueous humor drainage vein method (Shareef-Sharma model) and modification method；Additionally, also have the spontaneous mouse of some special germlines and transgenic technology to build glaucoma model, such as the mouse inbred lines of DBA/2J and AKXD-28/Ty, utilize the natural glaucoma model etc. that gene targeting builds.The most various models pathologic in terms of retinal ganglial cells (RGCs), optic nerve, retinal function is changed and be evaluated, assess the Positive and Negative Aspects of various model, preferably build, in chronic intraocular hypertension glaucoma Mechanism Study, the modeling animal agreed with mutually with clinic and modeling method provides foundation, the more mechanism of in-depth study chronic intraocular hypertension glaucoma, provides new thinking for its treatment.
Although the method making Bulbi hypertonia animal model has a lot, but current glaucoma animal model great majority are all acute high IOP models, although intraocular pressure raises, but its Bulbi hypertonia is held time short, and it is big to fluctuate, it is difficult to simulate the characteristic optic nerve lesion of glaucoma.
Summary of the invention
In order to overcome the defect of prior art, the invention provides the method for building up of a kind of chronic intraocular hypertension animal model.
The technical solution that the present invention uses is: the method for building up of a kind of chronic intraocular hypertension animal model, comprise the following steps: animal pattern bondage is lain on the back in operating-table by (1), art eye sterile drape, put eye speculum, rinse conjunctival sac, under art eye conjunctiva after the anesthesia of local profit, do superior rectus traction sutures and fix；
(2) timepiece dial telegoniometer is pressed, in 11 positions to 1 position edge ring bulbar conjunctiva incision, centered by 12 positions, place makees the shallow-layer scleral flap of 1/3 scleral thickness of size 4*4mm with limbus of corneae as substrate, size 3*3mm is done again below shallow-layer scleral flap, the Deep Layer of Sclera lobe of thickness 2/3 scleral thickness, and peel off to cornea direction, find Schlemm to manage and cut Schlemm pipe outer wall；
(3) in Schlemm pipe two ends, polymer hyaluronic acid is injected, fiber duct conduit is passed through opening, in 9 or 3 o ' clock orientation limbus of corneae at 1.0 mm, flat iris direction row paracentesis of anterior chamber, light pressure puncture orifice trailing edge, release water and reduce intraocular pressure, anterior chamber is reduced pressure and fiber duct is inserted after puncturing the broken ends of fractured bone of Schlemm pipe, 360 degree or 270 degree or 180 degree or 90 degree are detoured along Schlemm pipe, cut off conduit, it is placed in Schlemm blocking Schlemm pipe, stop ah outflow, sew up scleral flap, , paracentesis of anterior chamber mouth injection balance saline solution, sew up conjunctival flap, give anti-inflammatory drug, finally set up the animal model that intraocular pressure raises.
Described step (1) use dilution iodophor solution rinse conjunctival sac.
Described step (1) use the lignocaine of 0.4ml 2% carry out profit anesthesia in local under art eye conjunctiva.
Described step (1) use 30G syringe needle inject polymer hyaluronic acid in Schlemm pipe two ends.
In described step (3), fiber duct includes a cylindrical solid conduit, and described tube at one end is spherical structure.
The long 10cm of described fiber duct, diameter 200 μm, the spherical diameter of described tube at one end is 250 μm.
Described fiber duct uses polypropylene material to make.
The invention has the beneficial effects as follows: the invention provides the method for building up of a kind of chronic intraocular hypertension animal model, place material by operation and block its aqueous humor flow pass, intraocular pressure is caused to raise the chronic glaucoma animal model of optic nerve lesion, the chronic intraocular hypertension animal model produced by this method, its intraocular pressure can regulate and control according to the scope difference of blocking Schlemm.And the fiber duct of different specification size can be selected according to different animals kind Schlemm caliber, complete Schlemm blockage, thus produce the ocular hypertension model of many animals type.In chronic intraocular hypertension glaucoma Mechanism Study, preferably build the modeling animal agreed with mutually with clinic and modeling method, provide basis for carrying out chronic glaucoma optic nerve injury mechanism.
Accompanying drawing explanation
Fig. 1 is fiber duct structural representation of the present invention.
Detailed description of the invention
In conjunction with Fig. 1, the present invention is further described: operating procedure: operation needs a long 10cm diameter 200 μm solid fibers conduit being made by polypropylene material, the a diameter of 250 μm local bulkiness of conduit head end spherical, damages Schlemm tube wall tissue when preventing from intubating.
Animal pattern extremity bondage is lain on the back in operating-table, art eye routine disinfection drape, put eye speculum, dilution iodophor solution rinses conjunctival sac, take after locally moistening anesthesia under 0.4ml 2% lignocaine Rhizoma Atractylodis Macrocephalae eye conjunctiva, do superior rectus traction sutures to fix, by timepiece dial telegoniometer, in 11 positions to 1 position edge ring bulbar conjunctiva incision, centered by 12 positions, place makees the shallow-layer scleral flap of 1/3 scleral thickness of the size about 4*4mm with limbus of corneae as substrate, a size about 3*3mm, the Deep Layer of Sclera lobe of thickness about 2/3 scleral thickness is done again below shallow-layer scleral flap.And peel off to cornea direction, find Schlemm to manage and cut Schlemm pipe outer wall, in Schlemm pipe two ends, injecting polymer hyaluronic acid (Healon GV) with 30G syringe needle, enable the duct to easily by opening.In 9 or 3 o ' clock orientation limbus of corneae at 1.0 mm, flat iris direction row paracentesis of anterior chamber, light pressure puncture orifice trailing edge, releases appropriate aqueous humor and reduces intraocular pressure, and anterior chamber is reduced pressure and microtubular is inserted after puncturing the broken ends of fractured bone of Schlemm pipe, difference according to required target intraocular pressure, detour 360 degree or 270 degree or 180 degree or 90 degree along Schlemm pipe respectively, cut off conduit, be placed in Schlemm blocking Schlemm pipe, stop ah outflow, cause the model that its intraocular pressure raises.Finally with 10-0 polypropylene line tight suture scleral flap 4-6 pin, paracentesis of anterior chamber mouth injection balance saline solution is observed, and sews up with the non-leakage watertight that is considered as, then with 10-0 polypropylene suturing with thread management conjunctival flap 2 pin.The postoperative anti-inflammatory drug that gives, monitors intraocular pressure, prosthomere response situation.
The present invention places material by operation and blocks its aqueous humor flow pass, intraocular pressure is caused to raise the glaucoma animal model of optic nerve lesion, the chronic intraocular hypertension animal model produced by this method, its intraocular pressure can regulate and control according to the scope difference of blocking Schlemm.And the fiber duct of different specification size can be selected according to different animals kind Schlemm caliber, complete Schlemm blockage, thus produce the ocular hypertension model of many animals type..The fiber duct specification that lagophthalmos, the animal model of monkey eye use can use long 10cm diameter 200 μm, and conduit head end spherical diameter is 250 μm, the optional conduit specification matched with its Schlemm caliber of other animals.In chronic intraocular hypertension glaucoma Mechanism Study, preferably build the modeling animal agreed with mutually with clinic and modeling method, provide basis for carrying out chronic glaucoma optic nerve injury mechanism.
The above is only the preferred embodiment of the present invention, and protection scope of the present invention is not limited merely to above-described embodiment, and all technical schemes belonged under thinking of the present invention belong to protection scope of the present invention.It should be pointed out that, for those skilled in the art, some improvements and modifications without departing from the principles of the present invention, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (7)
1. the method for building up of a chronic intraocular hypertension animal model, it is characterised in that comprise the following steps: animal pattern bondage is lain on the back by (1), art eye sterile drape, puts eye speculum, rinses conjunctival sac, under art eye conjunctiva after the anesthesia of local profit, do superior rectus traction sutures and fix；
(2) timepiece dial telegoniometer is pressed, in 11 positions to 1 position edge ring bulbar conjunctiva incision, centered by 12 positions, place makees the shallow-layer scleral flap of 1/3 scleral thickness of size 4*4mm with limbus of corneae as substrate, size 3*3mm is done again below shallow-layer scleral flap, the Deep Layer of Sclera lobe of thickness 2/3 scleral thickness, and peel off to cornea direction, find Schlemm to manage and cut Schlemm pipe outer wall；
(3) in Schlemm pipe two ends, polymer hyaluronic acid is injected, fiber duct conduit is passed through opening, in 9 or 3 o ' clock orientation limbus of corneae at 1.0 mm, flat iris direction row paracentesis of anterior chamber, light pressure puncture orifice trailing edge, release water and reduce intraocular pressure, anterior chamber is reduced pressure and fiber duct is inserted after puncturing the broken ends of fractured bone of Schlemm pipe, 360 degree or 270 degree or 180 degree or 90 degree are detoured along Schlemm pipe, cut off conduit, it is placed in Schlemm blocking Schlemm pipe, stop ah outflow, sew up scleral flap, , paracentesis of anterior chamber mouth injection balance saline solution, sew up conjunctival flap, give anti-inflammatory drug, finally set up the animal model that intraocular pressure raises.
The method for building up of a kind of chronic intraocular hypertension animal model the most according to claim 1, it is characterised in that use dilution iodophor solution to rinse conjunctival sac in described step (1).
The method for building up of a kind of chronic intraocular hypertension animal model the most according to claim 1, it is characterised in that use the lignocaine of 0.4ml 2% to carry out profit anesthesia in local under art eye conjunctiva in described step (1).
The method for building up of a kind of chronic intraocular hypertension animal model the most according to claim 1, it is characterised in that use 30G syringe needle to inject polymer hyaluronic acid in Schlemm pipe two ends in described step (1).
The method for building up of a kind of chronic intraocular hypertension animal model the most according to claim 1, it is characterised in that in described step (3), fiber duct includes a cylindrical solid conduit, described tube at one end is spherical structure.
The method for building up of a kind of chronic intraocular hypertension animal model the most according to claim 5, it is characterised in that the long 10cm of described fiber duct, diameter 200 μm, the spherical diameter of described tube at one end is 250 μm.
The method for building up of a kind of chronic intraocular hypertension animal model the most according to claim 5, it is characterised in that described fiber duct uses polypropylene material to make.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610249471.5A CN105943186A (en) | 2016-04-21 | 2016-04-21 | Establishment method for chronic high intraocular pressure animal model |
| PCT/CN2017/078965 WO2017181835A1 (en) | 2016-04-21 | 2017-03-31 | Method for establishing chronic ocular hypertension animal model |
| JP2018532502A JP6505325B2 (en) | 2016-04-21 | 2017-03-31 | Method of producing chronic high intraocular pressure non-human animal model |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610249471.5A CN105943186A (en) | 2016-04-21 | 2016-04-21 | Establishment method for chronic high intraocular pressure animal model |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105943186A true CN105943186A (en) | 2016-09-21 |
Family
ID=56917874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610249471.5A Pending CN105943186A (en) | 2016-04-21 | 2016-04-21 | Establishment method for chronic high intraocular pressure animal model |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6505325B2 (en) |
| CN (1) | CN105943186A (en) |
| WO (1) | WO2017181835A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017181835A1 (en) * | 2016-04-21 | 2017-10-26 | 温州眼视光发展有限公司 | Method for establishing chronic ocular hypertension animal model |
| CN107981969A (en) * | 2017-12-29 | 2018-05-04 | 温州医科大学附属眼视光医院 | Drainage substitutes biomimetic scaffolds in a kind of glaucoma |
| CN109481071A (en) * | 2019-01-16 | 2019-03-19 | 沈阳眼产业技术研究院有限公司 | A kind of method for building up of chronic intraocular hypertension animal model |
| CN109907857A (en) * | 2019-02-28 | 2019-06-21 | 中国人民解放军第四军医大学 | A device for injecting polyester fiber microspheres in front of mouse eyeball |
| CN111053626A (en) * | 2019-12-26 | 2020-04-24 | 中国人民解放军总医院 | Molding method, animal model and application thereof |
| CN113133431A (en) * | 2021-02-25 | 2021-07-20 | 中南大学 | Establishment method, model and application of chronic ocular hypertension combined long-axis animal model |
| CN113273546A (en) * | 2021-02-25 | 2021-08-20 | 中南大学 | Application of lauromacrogol in preparation of chronic ocular hypertension animal model and animal model |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111110441A (en) * | 2020-01-08 | 2020-05-08 | 孙河 | An experimental rat episcleral vein injection device and method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
| CN102665619A (en) * | 2009-10-23 | 2012-09-12 | 孕体股份有限公司 | Contraceptive devices |
| CN202637223U (en) * | 2012-04-24 | 2013-01-02 | 东华大学 | Blocking type birth control device free of damaging fallopian tube organization |
| CN203355084U (en) * | 2013-07-10 | 2013-12-25 | 高广林 | Nasobiliary drainage tube |
| CN103932841A (en) * | 2011-06-16 | 2014-07-23 | 王宁利 | Schlemm canal expandable stent and combination bodies thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360399A (en) * | 1992-01-10 | 1994-11-01 | Robert Stegmann | Method and apparatus for maintaining the normal intraocular pressure |
| JP2002112664A (en) * | 2000-10-04 | 2002-04-16 | Koken Co Ltd | Method for making model animal of glaucoma |
| JP2003149236A (en) * | 2001-08-30 | 2003-05-21 | Santen Pharmaceut Co Ltd | Screening method for glaucoma remedy |
| WO2008112935A1 (en) * | 2007-03-13 | 2008-09-18 | University Of Rochester | Intraocular pressure regulating device |
| US8951221B2 (en) * | 2009-08-20 | 2015-02-10 | Grieshaber Ophthalmic Research Foundation | Method and device for the treatment of glaucoma |
| WO2011046949A2 (en) * | 2009-10-12 | 2011-04-21 | The Regents Of The University Of Colorado, A Body Corporate | Implants for reducing intraocular pressure |
| NL2004047C2 (en) * | 2010-01-04 | 2011-07-05 | D O R C Dutch Ophthalmic Res Ct International B V | An ophthalmic surgical device and a method of performing ophthalmic surgery. |
| BR112012030160B1 (en) * | 2010-05-27 | 2020-11-03 | Iscience Interventional Corporation | tool and device for total circumferential insertion for an implant in the schlemm canal of the eye |
| CN105943186A (en) * | 2016-04-21 | 2016-09-21 | 温州眼视光发展有限公司 | Establishment method for chronic high intraocular pressure animal model |
-
2016
- 2016-04-21 CN CN201610249471.5A patent/CN105943186A/en active Pending
-
2017
- 2017-03-31 WO PCT/CN2017/078965 patent/WO2017181835A1/en not_active Ceased
- 2017-03-31 JP JP2018532502A patent/JP6505325B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
| CN102665619A (en) * | 2009-10-23 | 2012-09-12 | 孕体股份有限公司 | Contraceptive devices |
| CN103932841A (en) * | 2011-06-16 | 2014-07-23 | 王宁利 | Schlemm canal expandable stent and combination bodies thereof |
| CN202637223U (en) * | 2012-04-24 | 2013-01-02 | 东华大学 | Blocking type birth control device free of damaging fallopian tube organization |
| CN203355084U (en) * | 2013-07-10 | 2013-12-25 | 高广林 | Nasobiliary drainage tube |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017181835A1 (en) * | 2016-04-21 | 2017-10-26 | 温州眼视光发展有限公司 | Method for establishing chronic ocular hypertension animal model |
| CN107981969A (en) * | 2017-12-29 | 2018-05-04 | 温州医科大学附属眼视光医院 | Drainage substitutes biomimetic scaffolds in a kind of glaucoma |
| CN107981969B (en) * | 2017-12-29 | 2023-07-14 | 苏州朗目医疗科技有限公司 | Replacement bionic bracket for glaucoma internal drainage |
| CN109481071A (en) * | 2019-01-16 | 2019-03-19 | 沈阳眼产业技术研究院有限公司 | A kind of method for building up of chronic intraocular hypertension animal model |
| CN109907857A (en) * | 2019-02-28 | 2019-06-21 | 中国人民解放军第四军医大学 | A device for injecting polyester fiber microspheres in front of mouse eyeball |
| CN109907857B (en) * | 2019-02-28 | 2023-10-31 | 中国人民解放军第四军医大学 | A device for injecting polyester fiber microspheres into the front of mouse eyeballs |
| CN111053626A (en) * | 2019-12-26 | 2020-04-24 | 中国人民解放军总医院 | Molding method, animal model and application thereof |
| CN111053626B (en) * | 2019-12-26 | 2021-08-20 | 中国人民解放军总医院 | A kind of modeling method and animal model and its application |
| CN113133431A (en) * | 2021-02-25 | 2021-07-20 | 中南大学 | Establishment method, model and application of chronic ocular hypertension combined long-axis animal model |
| CN113273546A (en) * | 2021-02-25 | 2021-08-20 | 中南大学 | Application of lauromacrogol in preparation of chronic ocular hypertension animal model and animal model |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018527147A (en) | 2018-09-20 |
| JP6505325B2 (en) | 2019-04-24 |
| WO2017181835A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105943186A (en) | Establishment method for chronic high intraocular pressure animal model | |
| Francis et al. | Novel glaucoma procedures: a report by the American Academy of Ophthalmology | |
| Francis et al. | Endoscopic ophthalmic surgery of the anterior segment | |
| Richter et al. | Minimally invasive glaucoma surgery: current status and future prospects | |
| US10238536B2 (en) | Ocular filtration devices, systems and methods | |
| US11707383B2 (en) | Inner drainage biomimetic stent for glaucoma and use thereof | |
| Vera et al. | Surgical approaches for implanting xen gel stent without conjunctival dissection | |
| Gelatt et al. | Surgical procedures of the lens and cataract | |
| Gurnani et al. | Manual small incision cataract surgery | |
| Hwang et al. | Combined phacoemulsification, foldable intraocular lens implantation, and 25-gauge transconjunctival sutureless vitrectomy | |
| CN113273546A (en) | Application of lauromacrogol in preparation of chronic ocular hypertension animal model and animal model | |
| Hu et al. | Glaucoma animal models in rabbits: State of the art and perspectives—A review | |
| Kyari | Managing cataract surgery in patients with glaucoma | |
| US10076443B2 (en) | Penetrating canaloplasty for treating angle-closure glaucoma | |
| Larsen et al. | Managing coexistent cataract and glaucoma with iStent | |
| CN211356212U (en) | An improved subbulbar injection needle for ophthalmology | |
| Kam et al. | New endoscopic surgical approach for anterior hyaloid dissection in phakic and pseudophakic patients | |
| Pašta | Laser therapy in ophthalmology | |
| Cavallini et al. | Bimanual microphacoemulsification and Acri. Smart intraocular lens implantation combined with vitreoretinal surgery | |
| Singh | Step-by-step: intratunnel phacofracture | |
| Laroche et al. | Retrobulbar/intraconal tube placement in patients with glaucoma: Ahmed FP-7 and tube extender case series with 1 year follow-up | |
| Aktas et al. | GATT international experience: Turkey | |
| Javed | Phacoemulsification under Topical Anesthesia Alone Versus Topical Anesthesia with Subconjunctival | |
| Gimbel et al. | Alternative techniques to be used with cataract surgery | |
| Muthukumaran | A Comparative Study of Post-Operative Astigmatism Induced by Phacoemulsification and Manual Small Incision Cataract Surgery at MVJMC & RH |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |